Related Experiment Videos
[Experimental and clinical study on chemotherapy for cervical adenocarcinoma]
M Takehara1, O Hayakawa, R Kudo
1Department of Obstetrics and Gynecology, Sapporo Medical University, School of Medicine.
Abstract:
We examined the effectiveness of 5 anticancer agents in nude mice transplanted with 4 kinds of uterine cervical adenocarcinoma. MMC, CDDP, ACM, ACD and VP-16 were selected. The therapeutic effects were assessed in terms of growth inhibition rates and histological effects in the transplanted tumors of nude mice. From this study, the following results were obtained: In single agent administration, MMC was effective in all tumors, and CDDP was effective in 3 kinds of tumors as indicated by the results showing growth inhibition rates. Histological findings for the agents did not correlate with therapeutic findings. In combined administration, MMC + CDDP was the most effective as indicated by the results showing growth inhibition rates; this combination showed an additive effect and MMC and CDDP were considered to be key drugs for treating cervical adenocarcinoma. On the basis of these results, we used combination chemotherapy with MMC, CDDP and ACM (PAM regimen) in high risk and advanced patients. We found an improved prognosis in advanced patients. There were one complete response and three partial responses in 7 advanced cases including one suffering recurrence. The combination therapy including MMC, CDDP and ACM was found to be effective against cervical adenocarcinoma.
Insights
Mitomycin C (MMC) and cisplatin (CDDP) show effectiveness against uterine cervical adenocarcinoma in mice. Combination chemotherapy, including ACM, improved prognosis in advanced patients.
Area of Science:
- Oncology
- Pharmacology
Context:
- Uterine cervical adenocarcinoma is a significant health concern.
- Evaluating novel therapeutic strategies is crucial for improving patient outcomes.
Purpose:
- To assess the efficacy of five anticancer agents (MMC, CDDP, ACM, ACD, VP-16) against uterine cervical adenocarcinoma xenografts in nude mice.
- To determine the effectiveness of single-agent and combination chemotherapy regimens.
Summary:
- Mitomycin C (MMC) demonstrated efficacy against all tested uterine cervical adenocarcinoma models.
- Cisplatin (CDDP) was effective in three of the four models.
- Combined administration of MMC and CDDP showed the highest growth inhibition rates, suggesting an additive effect and identifying them as key drugs.
- The PAM regimen (MMC, CDDP, ACM) demonstrated improved prognosis in advanced cervical adenocarcinoma patients, with one complete response and three partial responses in seven cases.
Impact:
- This study identifies key drugs (MMC, CDDP) and effective combination regimens for cervical adenocarcinoma treatment.
- The findings support the clinical application of combination chemotherapy (PAM regimen) in high-risk and advanced cervical adenocarcinoma patients.
- The research contributes to the development of more effective therapeutic strategies for cervical cancer.